دورية أكاديمية
أعرض في EDS

Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.

التفاصيل البيبلوغرافية
العنوان: Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.
المؤلفون: Scheinberg M; a Rheumatology Section - Orthopedics Department , Hospital Israelita Albert Einstein , São Paulo , Brazil., Pineda C; b Division of Musculoskeletal and Rheumatic Diseases , Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra , Mexico City , Mexico., Castañeda-Hernández G; c Department of Pharmacology , Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional , Mexico City , Mexico., Zarbá JJ; d Oncology Department , Hospital Centro de Salud Zenón J. Santillán , San Miguel de Tucumán , Argentina.; e Facultad de Medicina, Universidad Nacional de Tucumán , San Miguel de Tucumán , Argentina., Damião A; f Department of Gastroenterology , University of São Paulo Medical School , São Paulo , Brazil., Arantes LH Jr; g Pfizer Inc , New York , NY , USA., Jacobs I; g Pfizer Inc , New York , NY , USA.
المصدر: MAbs [MAbs] 2018 Aug/Sep; Vol. 10 (6), pp. 827-842. Date of Electronic Publication: 2018 Aug 29.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101479829 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1942-0870 (Electronic) Linking ISSN: 19420862 NLM ISO Abbreviation: MAbs Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, TX : Landes Bioscience
مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Biological Products/*therapeutic use , Biosimilar Pharmaceuticals/*therapeutic use , Inflammation/*drug therapy , Neoplasms/*drug therapy, Drug Approval/methods ; Drug Therapy/methods ; Drug Therapy/trends ; Forecasting ; Humans ; Inflammation/immunology ; Latin America ; Neoplasms/immunology
مستخلص: Biological therapies have revolutionized the treatment of several cancers and systemic immune-mediated inflammatory conditions. Expiry of patents protecting a number of biologics has provided the opportunity to commercialize highly similar versions, known as biosimilars. Biosimilars are approved by regulatory agencies via an independent pathway that requires extensive head-to-head comparison with the originator product. Biosimilars have the potential to provide savings to healthcare systems and expand patient access to biologics. In Latin American countries, regulatory frameworks for biosimilar approval have been introduced in recent years, and biosimilars of monoclonal antibody and fusion protein therapies are now emerging. However, the situation in this region is complicated by the presence of "non-comparable biotherapeutics" (also known as "intended copies"), which have not been rigorously compared with the originator product. We review the considerations for clinicians in Latin American countries, focusing on monoclonal antibody biosimilars relevant to oncology, rheumatology, gastroenterology, and dermatology.
References: Postgrad Med J. 2007 Apr;83(978):251-60. (PMID: 17403952)
Rheumatology (Oxford). 2017 Feb;56(2):187-197. (PMID: 27241704)
MAbs. 2018 Jan;10(1):166-176. (PMID: 29020508)
BMC Musculoskelet Disord. 2013 Sep 25;14:279. (PMID: 24067096)
Ann Rheum Dis. 2017 Mar;76(3):566-570. (PMID: 27624791)
Arq Gastroenterol. 2016 Apr-Jun;53(2):60-1. (PMID: 27305409)
Lancet Oncol. 2017 Jul;18(7):917-928. (PMID: 28592386)
Gastroenterol Rep (Oxf). 2015 Feb;3(1):63-8. (PMID: 25567472)
Expert Opin Drug Saf. 2015 Jan;14(1):63-72. (PMID: 25369769)
Am J Ther. 2016 Nov/Dec;23(6):e1903-e1910. (PMID: 26766293)
J Crohns Colitis. 2017 Jan;11(1):26-34. (PMID: 27927718)
Clin Exp Rheumatol. 2016 Sep-Oct;34(5):954. (PMID: 27383125)
Blood. 2012 Dec 20;120(26):5111-7. (PMID: 23093622)
World J Gastroenterol. 2015 Feb 14;21(6):1728-37. (PMID: 25684937)
Lancet. 2009 Jun 27;373(9682):2182-4. (PMID: 19560587)
Nat Rev Rheumatol. 2015 Dec;11(12):713-24. (PMID: 26282080)
Reumatol Clin. 2013 Mar-Apr;9(2):106-12. (PMID: 23337169)
Drug Des Devel Ther. 2015 Jun 24;9:3247-55. (PMID: 26150698)
Expert Rev Anticancer Ther. 2015 May;15(5):569-78. (PMID: 25818308)
Ann Rheum Dis. 2017 Jan;76(1):4-6. (PMID: 27566795)
MAbs. 2014;6(5):1163-77. (PMID: 25517302)
RMD Open. 2015 May 23;1(1):e000010. (PMID: 26509046)
Br J Dermatol. 2017 Apr;176(4):928-938. (PMID: 27787890)
Crit Rev Oncol Hematol. 2016 Aug;104:131-7. (PMID: 27354233)
Lancet Oncol. 2016 Jan;17(1):e31-8. (PMID: 26758759)
Cancer Chemother Pharmacol. 2018 Mar;81(3):515-527. (PMID: 29362903)
JAMA. 2017 Jan 3;317(1):37-47. (PMID: 27918780)
Clin Rheumatol. 2015 May;34(5):819-29. (PMID: 25501633)
Rev Panam Salud Publica. 2016 Aug;40(1):40-47. (PMID: 27706384)
BioDrugs. 2017 Feb;31(1):1-36. (PMID: 28078656)
Expert Opin Biol Ther. 2015;15(11):1633-46. (PMID: 26365396)
Br J Cancer. 2014 Oct 28;111(9):1693-702. (PMID: 24569469)
Ann Rheum Dis. 2013 Oct;72(10):1605-12. (PMID: 23687259)
Curr Rheumatol Rep. 2016 Mar;18(3):16. (PMID: 26951254)
Arthritis Res Ther. 2014 Dec 06;16(6):501. (PMID: 25677586)
Dermatol Online J. 2016 Sep 15;22(9):. (PMID: 28329605)
Autoimmun Rev. 2015 Sep;14(9):769-73. (PMID: 25936608)
Braz J Med Biol Res. 2018 Jan 11;51(3):e7214. (PMID: 29340530)
Aliment Pharmacol Ther. 2017 Apr;45(8):1043-1057. (PMID: 28239873)
Rev Panam Salud Publica. 2018 Feb 19;41:e129. (PMID: 29466518)
Ann Rheum Dis. 2017 Feb;76(2):346-354. (PMID: 27117698)
RMD Open. 2016 Feb 05;2(1):e000154. (PMID: 26870392)
Clin Rheumatol. 2015 Mar;34 Suppl 1:S59-66. (PMID: 26188617)
Lancet Haematol. 2017 Aug;4(8):e362-e373. (PMID: 28712940)
Arq Gastroenterol. 2015 Jan-Mar;52(1):76-80. (PMID: 26017088)
Pharmaceuticals (Basel). 2014 Sep 17;7(9):943-53. (PMID: 25232798)
Pharmaceuticals (Basel). 2014 May 07;7(5):530-44. (PMID: 24810947)
Nat Rev Rheumatol. 2012 Jun 05;8(7):430-6. (PMID: 22664834)
Blood. 2014 Nov 20;124(22):3191-6. (PMID: 25298038)
J Crohns Colitis. 2013 Aug;7(7):586-9. (PMID: 23623738)
Joint Bone Spine. 2014 Dec;81(6):471-7. (PMID: 24956990)
Curr Rheumatol Rep. 2016 Aug;18(8):50. (PMID: 27402107)
Reumatol Clin (Engl Ed). 2018 May - Jun;14(3):127-136. (PMID: 28807650)
Rheumatol Int. 2014 Jan;34(1):25-33. (PMID: 24057144)
Lancet Oncol. 2014 Apr;15(4):424-35. (PMID: 24602760)
J Dermatol. 2017 Jan;44(1):3-12. (PMID: 27461455)
Clin Rheumatol. 2012 Sep;31(9):1279-80. (PMID: 22918492)
Mult Scler J Exp Transl Clin. 2017 Mar 23;3(1):2055217317700668. (PMID: 28607755)
J Glob Oncol. 2016 Jul 20;3(3):201-207. (PMID: 28717761)
Lancet. 2017 Jun 10;389(10086):2304-2316. (PMID: 28502609)
Cancer. 2017 Apr 15;123(8):1313-1323. (PMID: 28182258)
Cancer Chemother Pharmacol. 2016 Dec;78(6):1317-1318. (PMID: 27752763)
Ann Rheum Dis. 2017 Jan;76(1):51-57. (PMID: 26150601)
Lancet Oncol. 2015 Oct;16(14):1405-38. (PMID: 26522157)
Rheumatol Int. 2016 May;36(5):613-25. (PMID: 26920148)
Ann Rheum Dis. 2013 Oct;72(10):1613-20. (PMID: 23687260)
Cancer Treat Rev. 2016 May;46:73-9. (PMID: 27135548)
J Oncol Pract. 2012 May;8(3):190-5. (PMID: 22942815)
Rev Panam Salud Publica. 2018 Feb 19;41:e78. (PMID: 29466527)
Ann Rheum Dis. 2017 Feb;76(2):355-363. (PMID: 27130908)
BioDrugs. 2016 Dec;30(6):489-523. (PMID: 27807766)
PLoS One. 2015 Mar 17;10(3):e0119683. (PMID: 25781999)
Int J Rheum Dis. 2016 Nov;19(11):1157-1168. (PMID: 26176644)
Pharmaceuticals (Basel). 2017 Jan 28;10(1):. (PMID: 28134851)
Clin Rheumatol. 2015 Apr;34(4):635-40. (PMID: 25673060)
فهرسة مساهمة: Keywords: Antibodies; Latin America; biological therapy; biosimilar pharmaceuticals; dermatology; gastroenterology; monoclonal; neoplasms; rheumatology
المشرفين على المادة: 0 (Antibodies, Monoclonal)
0 (Biological Products)
0 (Biosimilar Pharmaceuticals)
تواريخ الأحداث: Date Created: 20180830 Date Completed: 20190225 Latest Revision: 20230928
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6152448
DOI: 10.1080/19420862.2018.1484977
PMID: 30156950
قاعدة البيانات: MEDLINE
الوصف
تدمد:1942-0870
DOI:10.1080/19420862.2018.1484977